Related Experiment Video
Updated: Jun 25, 2026
Unilateral Ureteral Obstruction Model for Investigating Kidney Interstitial Fibrosis
Published on: April 25, 2025
[Reversal of renal fibrosis: lessons from experimental models]
Jean-Claude Dussaule1, Christos Chatziantoniou
1Unité INSERM 702, Hôpital Tenon, Paris, France.
Abstract:
New insights into the pathophysiological mechanisms of renal disease progression have been provided by recent experimental studies. It is now clear that angiotensin II is a key factor in the development of renal fibrosis, and that angiotensin II antagonists can slow the progression of renal disease in humans. However, other profibrotic agents, such as TGF beta, endothelin, and activated growth factor receptors have also been implicated. In vivo experimental studies have shown that renal fibrosis can be reversed. Based on the results of genetic and pharmacological antagonism of profibrotic agents in animals, this review describes potential future therapeutics that might limit the progression of human nephropathies, or even reverse them.
Insights
New research shows angiotensin II drives kidney fibrosis. Therapies targeting this and other fibrotic agents may slow or reverse kidney disease progression in humans.
Area of Science:
- Nephrology
- Pathophysiology
- Fibrosis Research
Context:
- Recent experimental studies offer new insights into renal disease progression.
- Angiotensin II is identified as a critical factor in renal fibrosis development.
- Other profibrotic agents like TGF-beta and endothelin are also implicated.
Purpose:
- To review potential therapeutic strategies for limiting or reversing human nephropathies.
- To discuss findings from animal studies on genetic and pharmacological antagonism of profibrotic agents.
Summary:
- Angiotensin II antagonists slow human renal disease progression.
- In vivo studies demonstrate the reversibility of renal fibrosis.
- Future therapeutics may target multiple profibrotic pathways.
Impact:
- Provides a basis for developing novel treatments for kidney diseases.
- Highlights the potential for reversing established renal fibrosis.
- Offers hope for improved management of human nephropathies.
